Alpha-Methyldopa May Attenuate Insulin Demand in Women with Gestational Diabetes Treated with Betamethasone
Gestational diabetes mellitus (GDM) is associated with hypertensive disorders in pregnancy. Alpha-methyl-DOPA (αMD) is a commonly used medication for hypertension in pregnant women. This medication may be associated with alteration in insulin resistance and glucose homeostasis. The aim of the present study was to investigate in 152 pregnant women whether the demands of exogenous insulin in glucocorticoid-treated women during pregnancy are different between those with GDM and hypertension treated with αMD and those without hypertension. In the group of women with GDM under insulin treatment, who received αMD for hypertension, the increase in insulin needs was relatively lower by at least 30% of the pre-admission insulin dose compared to all of the remaining women not receiving αMD in the same group (9 women vs. 50 women, p = 0.035). Our work raises the hypothesis that αMD can favorably modulate insulin sensitivity in the third trimester of pregnancy in previously insulin-treated women with gestational diabetes who receive glucocorticoids.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2022 |
|---|---|
| Erschienen: |
2022 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:10 |
|---|---|
| Enthalten in: |
Healthcare (Basel, Switzerland) - 10(2022), 1 vom: 10. Jan. |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Kakoulidis, Ioannis [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Gestational diabetes |
|---|
| Anmerkungen: |
Date Revised 28.01.2022 published: Electronic Citation Status PubMed-not-MEDLINE |
|---|
| doi: |
10.3390/healthcare10010135 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM335869394 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM335869394 | ||
| 003 | DE-627 | ||
| 005 | 20231225230836.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2022 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.3390/healthcare10010135 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1119.xml |
| 035 | |a (DE-627)NLM335869394 | ||
| 035 | |a (NLM)35052298 | ||
| 035 | |a (PII)135 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Kakoulidis, Ioannis |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Alpha-Methyldopa May Attenuate Insulin Demand in Women with Gestational Diabetes Treated with Betamethasone |
| 264 | 1 | |c 2022 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Revised 28.01.2022 | ||
| 500 | |a published: Electronic | ||
| 500 | |a Citation Status PubMed-not-MEDLINE | ||
| 520 | |a Gestational diabetes mellitus (GDM) is associated with hypertensive disorders in pregnancy. Alpha-methyl-DOPA (αMD) is a commonly used medication for hypertension in pregnant women. This medication may be associated with alteration in insulin resistance and glucose homeostasis. The aim of the present study was to investigate in 152 pregnant women whether the demands of exogenous insulin in glucocorticoid-treated women during pregnancy are different between those with GDM and hypertension treated with αMD and those without hypertension. In the group of women with GDM under insulin treatment, who received αMD for hypertension, the increase in insulin needs was relatively lower by at least 30% of the pre-admission insulin dose compared to all of the remaining women not receiving αMD in the same group (9 women vs. 50 women, p = 0.035). Our work raises the hypothesis that αMD can favorably modulate insulin sensitivity in the third trimester of pregnancy in previously insulin-treated women with gestational diabetes who receive glucocorticoids | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a gestational diabetes | |
| 650 | 4 | |a human | |
| 650 | 4 | |a hypertension | |
| 650 | 4 | |a insulin | |
| 650 | 4 | |a methyldopa | |
| 650 | 4 | |a pregnancy-induced | |
| 700 | 1 | |a Thomopoulos, Costas |e verfasserin |4 aut | |
| 700 | 1 | |a Ilias, Ioannis |e verfasserin |4 aut | |
| 700 | 1 | |a Stergiotis, Stefanos |e verfasserin |4 aut | |
| 700 | 1 | |a Togias, Stefanos |e verfasserin |4 aut | |
| 700 | 1 | |a Michou, Aikaterini |e verfasserin |4 aut | |
| 700 | 1 | |a Milionis, Charalampos |e verfasserin |4 aut | |
| 700 | 1 | |a Venaki, Evangelia |e verfasserin |4 aut | |
| 700 | 1 | |a Koukkou, Eftychia |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Healthcare (Basel, Switzerland) |d 2013 |g 10(2022), 1 vom: 10. Jan. |w (DE-627)NLM253742684 |x 2227-9032 |7 nnns |
| 773 | 1 | 8 | |g volume:10 |g year:2022 |g number:1 |g day:10 |g month:01 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.3390/healthcare10010135 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 10 |j 2022 |e 1 |b 10 |c 01 | ||